Spotlight Sessions

Spotlight Sessions are thought leadership opportunities at AMCP national meetings offered in 15-minute, 30-minute, and 60-minute

The RWE Arena and Spotlight Stage are located in Hall B in the Music City Center and include programming on Tuesday, April 14 from 11am-5:15pm and on Wednesday, April 15 from 9:30am-2:30pm.

Additional program details and faculty information can be found on the AMCP 2026 mobile app, available at the end of March.

Tuesday, April 14 | 11-11:30am | The Spotlight Stage

Precision Medicine Isn’t Precise Without Testing

Behind every targeted therapy is a testing journey that too often falls apart. This spotlight explores where patients fall through the cracks—and how AMCP’s Precision Medicine Initiative is bringing stakeholders together to close the gaps and get precision medicine right. From inconsistent terminology to misaligned coverage decisions, precision medicine can get lost in translation. Learn how AMCP is simplifying the conversation and creating practical tools to support clearer, more consistent biomarker testing access.

Brought to you by AMCP

Tuesday, April 14 | 11-11:30am | RWE Arena

Real-World Identification of Obesity: Development and Internal Validation of a Claims-Based Machine Learning Algorithm

This study addresses a practical managed care evidence gap: obesity is substantially under-identified in claims when relying on diagnosis codes alone. Using a large linked real-world dataset of commercial and Medicare Advantage claims enriched with EHR BMI, labs, and area-level SDOH, the investigators developed a machine-learning algorithm to identify obesity more accurately. The key message is that the model showed clear improvement over diagnosis codes alone, with materially higher sensitivity and strong overall discrimination, while maintaining reasonable specificity and PPV. This makes the work highly relevant for payer analytics, outcomes research, population health management, and targeting obesity-related interventions when BMI is not directly available in claims.

Featuring:
Hiangkiat (Jason) Tan, BSPharm, MS
Senior Research Scientist
Carelon Research

Brought to you by AMCP Research Institute

Tuesday, April 14 | 11:45am-12:30pm | The Spotlight Stage

Optimizing the Treatment of Chronic Hand Eczema in Managed Care

Join Us for a Critical Update on Chronic Hand Eczema Management

This session will provide an overview of Chronic Hand Eczema (CHE) and considerations for its management within managed care settings.

The presentation will include a discussion of recent research efforts, including CHECK-US and RWEAL-US, as well as evolving perspectives on treatment approaches and unmet needs in CHE.

Attendees will also hear from a panel of experts representing health economics, clinical practice, and managed care, who will share insights on current challenges, treatment pathways, and considerations for care delivery.

This session is intended for stakeholders involved in formulary decision-making, specialty pharmacy management, and care pathway development, and will offer an opportunity to engage with emerging data and expert perspectives in CHE management.

Featuring:
Diana Brixner, RPh, PhD, FAMCP
Professor Emeritus, University of Utah
Principal, Millcreek Outcomes Group

Suzan Tsang, PharmD
Director, Medical Outcomes
LEO Pharma

Aseel Bin Sawad, PharmD, MSc, MCR, MS, PhD, DBA
AD, Health Care Systems & HEOR
LEO Pharma

Jeff Dunn, PharmD, MBA
Chief Clinical Officer,
Cooperative Benefits Group

Sponsored by: Cencora

Wednesday, April 15 | 10-10:30am | The Spotlight Stage

Did you know? The Behind‑the‑Scenes Forces Shaping Our Work

Ever wonder who decides what an ICD‑10 code is — or how in the world do patients get access to therapies before they’re approved in a country? In this “Did You Know?” session, we’ll unpack two behind-the-scenes topics that have a real impact on evidence, policy, access, and day-to-day business decisions.

First, we’ll explore how ICD‑10 codes evolve over time and why those updates can have a meaningful ripple effect across coverage, evidence, and day-to-day decision-making. Then we’ll shift to global early access programs highlighting global access pathways that exist, in the US, EU and other global markets, for both compassionate use and named patient sales. Understanding these pathways, patient populations that can be accessed, and the nuanced regulatory language in these markets, can provide an opportunity to connect patients in need to innovative therapies, otherwise unavailable in many global markets.

We’ll keep it practical, interactive, and focused on what these processes mean for real-world work.

Brought to you by AMCP

Wednesday, April 15 | 10:30-11am | RWE Arena

Delivering Relevant and Reliable Real-World Evidence to Support Medicare Drug Price Negotiations

As the U.S. Centers for Medicare and Medicaid Services (CMS) implements the Medicare Drug Price Negotiation Program under the Inflation Reduction Act (IRA), a key challenge is ensuring that price determinations are informed, in a transparent manner, by high-quality, relevant evidence on how selected drugs perform in the Medicare population. While CMS has made meaningful strides in articulating how it will assess clinical benefit and comparative effectiveness, greater clarity is needed—particularly regarding the use and interpretation of real-world evidence (RWE) as part of the negotiation process. How CMS should assess RWE during price negotiations and actively shape upstream evidence generation through clearer expectations and guidance? This session will provide professional and up-to-date perspectives on relevant work published to date and how CMS can offer manufacturers and other stakeholders effective signals and pathways to reduce uncertainty around evidence expectations.

Featuring:
Rachele Hendricks-Sturrup, DHSc, MSc, MA
Research Director
Duke-Robert J. Margolis Institute for Health Policy

Brought to you by AMCP Research Institute

Wednesday, April 15 | 10:45-11:30am | The Spotlight Stage

Impact of ADA 2026 Guidelines on Patient Care and Metabolic Health: Operational Strategies for Managed Care Professionals

Learning Objectives:

Define the scope and drivers of the metabolic health crisis in the United States and its implications for patients and the healthcare system.
Summarize key updates from the 2026 American Diabetes Association Standards of Care in Diabetes and their impact on clinical practice.
Explore managed care strategies that support improved metabolic health outcomes across populations.

Brought to you by AMCP and sponsored by Dexcom

Wednesday, April 15 | 11-11:30am | RWE Arena

Designing Real World Evidence Studies: The Regulatory Landscape

Real World Evidence (RWE) is rapidly reshaping decisions across the FDA, payers, and healthcare, but how can you actually design RWE studies that meet regulatory requirements, mitigate bias, and present high-quality findings? Unpacking the evolving U.S. regulatory landscape must begin by reviewing the history of the FDA and RWE and the resulting guidance ranging from FDAMA §114 to HIPAA to FDA Study Design. Current guidance specifies how to build RWE protocols, reduce risk and ensure de-identification for patients, and establish that evidence is "fit-for-purpose" for the question at hand. In addition, transparency, harmonization of data elements, adjustment for common biases, and methods to prevent potential misapplication of findings are covered. This presentation will mix ethical considerations with sound research design with the past, present, and potential future of RWE regulation in the United States.

Featuring:
Kevin Kallmes
Chief Executive Officer and Co-Founder
Nested Knowledge, Inc.

Brought to you by AMCP Research Institute

Wednesday, April 15 | 11:45am-12:15pm | The Spotlight Stage

Introducing a New Standard for Payer Drug Evaluation: The Payer Value Index (PVI) in Collaboration with AMCP

The AMCP Format standardized how manufacturers communicate evidence to payers and is now widely adopted across the industry. Today, AMCP and the Payer Value Index (PVI) are introducing a new approach for how payers and healthcare decision-makers evaluate drug value—through an independent, transparent, and payer-centric methodology.

In this session, we will demonstrate how PVI works and how it supports structured evidence and value assessment across clinical, economic, and patient-centered dimensions. We will also show how PVI analyses are integrated into payer-centric AMCP eModels to enable plan-specific economic evaluation. We will introduce the AMCP PVI Payer council who will work to provide guidance on the methodology, payer needs and work with payer feedback.

Payers are invited to participate in the AMCP PVI Evidence & Value Innovation Program, an open initiative providing access to PVI assessments and AMCP eModels across 100+ therapies. Participants will have the opportunity to evaluate, apply, and provide feedback on this approach—helping shape the future of evidence and value assessment in managed care.

Featuring:
Allen Lising
Strategic Advisor
Digital Health Outcomes

Jeff Dunn, PharmD, MBA
Chief Clinical Officer,
Cooperative Benefits Group

Brought to you by Digital Health Outcomes

Wednesday, April 15 | 12-1:15pm | Invitation-Only

The Evolving Treatment Landscape of Hemophilia: Key Stakeholder Perspectives

Panel discussion on the current treatment landscape of hemophilia to understand the remaining unmet needs and challenges from a broad range of perspectives. The session will include an overview of hemophilia management, a discussion on the cost considerations and challenges in access to care, and an opportunity for collaboration and networking across industry stakeholders.

Spotlight Sessions

Questions?

Address

Phone